Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8NAC3
UPID:
I17RC_HUMAN
Alternative names:
Interleukin-17 receptor homolog; Interleukin-17 receptor-like protein; ZcytoR14
Alternative UPACC:
Q8NAC3; A8BWC1; A8BWC9; A8BWD5; E9PHG1; E9PHJ6; Q6UVY3; Q6UWD4; Q8NFS1; Q9BR97
Background:
Interleukin-17 receptor C (IL-17RC), also known as Interleukin-17 receptor homolog, plays a pivotal role in the immune system. It acts as a receptor for IL17A and IL17F, cytokines crucial for antimicrobial defense and tissue integrity. IL-17RC's involvement in signaling pathways like NF-kappa-B and MAPkinase underscores its importance in immune responses, particularly in neutrophil activation and recruitment.
Therapeutic significance:
IL-17RC's association with familial Candidiasis, a condition marked by impaired immune responses to fungal infections, highlights its therapeutic potential. Targeting IL-17RC could lead to innovative treatments for immune disorders and enhance our ability to combat fungal infections.